Analytical Preparation: Standard Operating Procedures for Peptide Reconstitution and Aliquot Management

This procedure applies to the preparation of aqueous stock and working solutions from lyophilized peptide reference materials for controlled in vitro laboratory screening. It covers mass-concentration arithmetic, molar-concentration arithmetic, solvent selection and introduction, serial dilution design, and aliquot storage. It is written to be adopted directly as a local work instruction and adapted to a specific assay context.

Two prerequisites must be satisfied before any step below is executed. First, the vial must have been equilibrated to ambient temperature while sealed, as condensation onto a cold lyophilized cake raises water activity before dissolution and compromises any material not used immediately. Second, the lot's certificate of analysis must have been resolved and the nominal peptide content confirmed, because every calculation in this document takes that content as its input.

Throughout, mass concentration is expressed in milligrams per millilitre and molar concentration in moles per litre. The two are not interchangeable and the conversion between them requires the molecular weight, which is compound-specific and published for each catalogue item on its product page and certificate.

The governing relationship is a single expression. Mass concentration equals peptide mass divided by solvent volume, conventionally written C = m / V. With mass in milligrams and volume in millilitres, the concentration is in milligrams per millilitre. Every reconstitution decision reduces to choosing two of these three quantities and solving for the third.

In practice the peptide mass is fixed by the vial and the target concentration is fixed by the assay, so the quantity being solved for is almost always the solvent volume: V = m / C. A 10 mg vial to be brought to 5 mg/mL requires 10 ÷ 5 = 2 mL of diluent. The same vial to 2 mg/mL requires 5 mL. The arithmetic is trivial; the errors are not arithmetic errors but unit errors, and they are almost always a factor of one thousand — milligrams read as micrograms, or millilitres as microlitres. Writing the units explicitly at every line of the calculation, rather than carrying bare numbers, eliminates the entire class.

A second and subtler source of error is treating the vial's nominal label mass as the exact peptide mass. Lyophilized preparations may contain residual counter-ions, typically acetate or trifluoroacetate from the purification step, and residual moisture. Where an assay demands high absolute accuracy rather than internal consistency, the peptide content stated on the certificate should be used in place of the nominal label mass, and the difference propagated through every subsequent dilution. For comparative work in which all conditions derive from the same stock, the nominal mass is normally sufficient because the systematic offset cancels.

In vitro screening is normally designed in molar rather than mass terms, because receptor occupancy, enzyme kinetics and binding equilibria are governed by the number of molecules present rather than their aggregate mass. Two peptides at identical mass concentration are at very different molar concentrations if their molecular weights differ, and comparing them on a mass basis produces a systematically misleading result.

The conversion is molar concentration equals mass concentration divided by molecular weight. Carrying the units through explicitly: a concentration in grams per litre divided by a molecular weight in grams per mole yields moles per litre. Because laboratory work is usually conducted in milligrams per millilitre — which is numerically identical to grams per litre — the practical form is convenient. A solution at C mg/mL of a peptide of molecular weight M g/mol has a molar concentration of C ÷ M mol/L.

A worked example makes the scale concrete. BPC-157 has molecular formula C62H98N16O22 and an average molecular weight of 1419.55 g/mol. A 10 mg vial reconstituted in 2 mL gives a mass concentration of 5 mg/mL, which is 5 g/L. Dividing by 1419.55 g/mol gives 3.52 × 10⁻³ mol/L, or 3.52 mM. To reach a 10 µM working concentration from that stock requires a dilution factor of 3.52 × 10⁻³ ÷ 10 × 10⁻⁶ = 352-fold.

The same calculation for a substantially larger molecule shows why the conversion cannot be skipped. Retatrutide, supplied as GLP-3 RT, has molecular formula C172H265N43O55 and an average molecular weight of 4113.64 g/mol. A 5 mg/mL solution of that material is 5 ÷ 4113.64 = 1.22 × 10⁻³ mol/L, or 1.22 mM — roughly a third of the molar concentration of the BPC-157 stock at the same mass concentration. Designing a comparative screen on mass concentration alone would introduce a threefold molar discrepancy before a single measurement was taken.

Where a dilution factor is awkward, the standard remedy is an intermediate stock rather than an attempt to pipette an impractically small volume. Transferring less than approximately 2 µL with an air-displacement pipette introduces relative error that dominates the measurement, and the correct response is to perform the dilution in two stages of manageable magnitude.

Diluent choice is dictated by the intended working period and the downstream assay. Sterile laboratory water is the appropriate choice for a solution prepared and consumed in a single session, contributing nothing but water to the matrix. A bacteriostatic laboratory diluent, preserved with benzyl alcohol, is appropriate where a solution will be accessed repeatedly over a working period, since the preservative suppresses microbial proliferation across multiple entries into the same vial. That preservative is itself a matrix component, and its compatibility with the downstream assay must be confirmed before it is introduced — some cell-based systems are sensitive to benzyl alcohol at concentrations well below those present in a standard bacteriostatic preparation. Buffered saline is used where ionic strength or pH must be controlled to match the assay matrix.

The mechanical technique of introducing that solvent is not incidental. Peptides in solution are susceptible to shear-induced denaturation and to interfacial adsorption, and the air-liquid interface generated by vigorous agitation is where both occur most readily. Directing a stream of diluent straight down onto a lyophilized cake, or shaking a vial to accelerate dissolution, generates exactly the conditions that produce foaming, aggregation and irreproducible recovery. Visible foam in a reconstituted vial is direct evidence that the interface has been expanded far beyond what dissolution required.

The correct technique is to direct the diluent down the interior wall of the vial so that it flows onto the cake rather than impinging on it, then to allow dissolution to proceed largely unaided. Most correctly lyophilized peptide cakes dissolve within a few minutes with no more assistance than slow inversion or gentle swirling. Where dissolution is incomplete after that interval, the appropriate response is additional standing time at ambient temperature, not increased agitation. A cake that will not dissolve gently is reporting something — collapse from a prior thermal excursion, or moisture uptake — and forcing it into solution destroys that signal without addressing its cause.

Vortexing and sonication are occasionally specified in published protocols for particular materials. Both deposit substantial energy into the solution and should be applied only where a documented method for that specific compound requires them, at the shortest effective duration, and never as a default response to slow dissolution.

Every reconstituted stock should be subdivided into single-use aliquots in the same session in which it is prepared. The rationale is the cumulative damage of freeze-thaw cycling: each cycle concentrates solutes in the shrinking unfrozen fraction, transiently shifts local pH as buffer components crystallise at different rates, and generates ice-water interfaces at which peptides adsorb and unfold. None of that is reversed by refreezing. Aliquoting converts an unbounded number of cycles into exactly one per aliquot.

Aliquot volume should be set by the largest single experimental draw the workflow requires, with a small allowance for pipetting losses, and no larger. Oversized aliquots reintroduce the problem they were meant to solve, because the remainder is either wasted or refrozen. Undersized aliquots force multiple thaws for a single experiment, which is the same failure by a different route. In practice, sizing to the largest routine draw and accepting occasional waste is the correct trade.

Adsorptive loss to container surfaces is a real and frequently overlooked effect at low concentrations. Peptides adsorb to polypropylene and to glass, and at working concentrations in the low micromolar range and below the fraction lost to the vessel wall can be significant relative to the amount in solution. Low-binding polypropylene vessels mitigate this. Where an assay operates at very low concentration, preparing working dilutions immediately before use rather than storing them is more reliable than any container choice.

Labelling is part of the procedure rather than an afterthought, because an unlabelled aliquot is unusable in any traceable workflow. Each aliquot must carry the compound identity, the lot number, the concentration in the units in which it was prepared, the diluent, and the preparation date. The lot number in particular is what binds the aliquot back to its certificate of analysis and its position in the batch verification index, and without it the analytical provenance established by the supplier terminates at the moment of reconstitution.

Concentration-response screening requires a geometric series of concentrations spanning the range of interest, and serial dilution is the standard method of generating one. The relationship at each step is the dilution equation C₁V₁ = C₂V₂, in which a volume V₁ of a solution at concentration C₁ is combined with diluent to a final volume V₂, producing concentration C₂. A tenfold step transfers one part stock to nine parts diluent; a twofold step transfers equal volumes.

The characteristic weakness of serial dilution is error propagation. Because each step takes the preceding step as its input, a pipetting error at any point is carried forward into every subsequent concentration and compounds multiplicatively. A systematic 2 % transfer error is negligible at the first point and material by the eighth. Three controls limit this: calibrated pipettes used within their optimal volume range rather than at the extremes, adequate mixing at every step before the next transfer is drawn, and a fresh tip for each transfer to prevent carryover from the more concentrated preceding tube.

For series spanning several orders of magnitude, preparing independent dilutions from the stock at each decade, rather than one continuous chain, is materially more accurate. It costs a little more stock and it stops error accumulating along the whole series. Where the highest concentration point requires a large dilution from stock, an intermediate dilution should be prepared first so that every transfer volume in the working series falls within the reliable range of the pipette in use.

Mixing between steps is the control most often skipped and least often documented. A transfer drawn from an incompletely mixed tube samples a concentration gradient rather than the intended concentration, and the resulting error is invisible because the arithmetic is correct. Gentle inversion or slow pipette mixing, sufficient to homogenise without foaming, should be performed and recorded at every step.